$5.16 -0.12 (%) Orexigen Therapeutics Inc - NASDAQ

Sep. 12, 2014 | 04:00 PM

Partner Headlines

  1. Takeda And Orexigen Announce FDA Approval of Contrave Extended-release Tablets For Chronic Weight Management

    Benzinga | Sep. 11, 2014 | 07:01AM EST
  2. Benzinga's Top #PreMarket Losers

    Benzinga | Jul. 30, 2014 | 08:13AM EST
  3. Events Scheduled for Week of Jun. 16th to Jun. 20th

    Benzinga | Jun. 17, 2014 | 10:48AM EST
  4. FDA delays Orexigen drug

    IBD | Jun. 11, 2014 | 18:57PM EST
  5. Mid-Afternoon Market Update: ULTA Salon Remains Steady After Strong Results; Orexigen Still Down 15%

    Benzinga | Jun. 11, 2014 | 15:48PM EST
  6. Mid-Day Market Update: ULTA Salon Rises After Strong Results; Orexigen Shares Slide

    Benzinga | Jun. 11, 2014 | 12:34PM EST
  7. Orexigen Obesity Drug Decision Delayed By FDA

    IBD | Jun. 11, 2014 | 11:55AM EST
  8. Orexigen Shares Plummet Following FDA Decision; Competition Gets A Bump

    Benzinga | Jun. 11, 2014 | 11:24AM EST
  9. Mid-Morning Market Update: Markets Drop; H&R Block Posts Higher Profit

    Benzinga | Jun. 11, 2014 | 10:13AM EST
  10. Morning Market Losers

    Benzinga | Jun. 11, 2014 | 09:46AM EST
  11. Benzinga's Top #PreMarket Losers

    Benzinga | Jun. 11, 2014 | 08:09AM EST
  12. US Stock Futures Tumble; World Bank Lowers Global Growth Outlook

    Benzinga | Jun. 11, 2014 | 07:31AM EST
  13. Earnings Scheduled For March 12, 2014

    Benzinga | Mar. 12, 2014 | 05:09AM EST
  14. Benzinga's Top #PreMarket Losers

    Benzinga | Dec. 2, 2013 | 08:43AM EST
  15. Benzinga's Top #PreMarket Gainers

    Benzinga | Nov. 26, 2013 | 08:10AM EST
  16. Mid-Afternoon Market Update: Markets Turn Back as Momentum Stocks Drop

    Benzinga | Nov. 25, 2013 | 15:48PM EST
  17. Mid-Day Market Update: SeaDrill Drops On Downbeat Earnings; Giant Interactive Shares Spike Higher

    Benzinga | Nov. 25, 2013 | 13:04PM EST
  18. Benzinga's Top #PreMarket Gainers

    Benzinga | Nov. 25, 2013 | 08:12AM EST
  19. Orexigen Announces Successful Interim Analysis of Contrave Light Study, Will Resubmit Contrave NDA to FDA

    Benzinga | Nov. 25, 2013 | 07:04AM EST
  20. Orexigen, Takeda Report Multiple Contrave Data Presentations at ObesityWeek

    Benzinga | Nov. 11, 2013 | 16:31PM EST
  21. Obesity drugs up on report

    IBD | Oct. 3, 2013 | 18:50PM EST
  22. Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and Raises PT

    Benzinga | Oct. 3, 2013 | 16:42PM EST
  23. Obesity Drug Stocks Jump As Cowen Gets Bullish

    IBD | Oct. 3, 2013 | 13:20PM EST
  24. Benzinga's Top Initiations

    Benzinga | Oct. 3, 2013 | 07:29AM EST
  25. Orexigen Submits Contrave Marketing Authorization Application to EMA

    Benzinga | Oct. 3, 2013 | 07:06AM EST
  26. Mid-Afternoon Market Update: DSW Rises as the NASDAQ Gets Crushed

    Benzinga | Aug. 27, 2013 | 15:37PM EST
  27. Benzinga's Top Pre-Market Gainers

    Benzinga | Aug. 27, 2013 | 08:20AM EST
  28. Orexigen Reports Progress on Resubmission of Contrave NDA, Sees Potential Approval in Early 2014

    Benzinga | Jan. 7, 2013 | 01:43AM EST
  29. Orexigen Concludes Light Study Patient Screening, to Randomize ~9,000 Patients, Sees Resubmission in Q4

    Benzinga | Dec. 18, 2012 | 01:36AM EST
  30. Orexigen Therapeutics Inc. Reports Operating Results (10-Q)

    GuruFocus | Nov. 9, 2012 | 01:33AM EST
  31. Orexigen Therapeutics Announces Proposed Public Offering of Common Stock

    Benzinga | Oct. 24, 2012 | 10:19AM EST
  32. Orexigen Therapeutics Receives Positive Dispute Response from FDA for Contrave

    Benzinga | Oct. 22, 2012 | 01:06AM EST
  33. Who Needs Diet and Exercise? Health Plans Cover New Vivus Obesity Drug

    YCharts | Oct. 4, 2012 | 03:51AM EST
  34. Benzinga's Top Pre-Market Losers

    Benzinga | Sep. 17, 2012 | 02:21AM EST
  35. US Stock Futures Down; Crude Oil Drops

    Benzinga | Sep. 17, 2012 | 00:11AM EST
  36. Stocks To Watch For September 17, 2012

    Benzinga | Sep. 16, 2012 | 20:06PM EST
  37. Benzinga's Top Initiations

    Benzinga | Sep. 6, 2012 | 01:27AM EST
  38. Benzinga's Top Pre-Market Gainers

    Benzinga | Sep. 5, 2012 | 02:11AM EST
  39. Orexigen Therapeutics Announces Continued Rapid Enrollment into the Light Study

    Benzinga | Sep. 5, 2012 | 00:40AM EST
  40. Orexigen Therapeutics Inc. (OREX) President and CEO Michael Narachi sells 150,000 Shares

    GuruFocus | Jul. 19, 2012 | 17:19PM EST
  41. Benzinga's Top Pre-Market Gainers

    Benzinga | Jul. 17, 2012 | 02:16AM EST
  42. Vivus Rises Ahead Of FDA Vote On Qnexa Diet Drug

    IBD | Jul. 16, 2012 | 09:20AM EST
  43. Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby ...

    GuruFocus | Jul. 15, 2012 | 18:35PM EST
  44. Orexigen Therapeutics Inc. (OREX) President and CEO Michael Narachi sells 150,000 Shares

    GuruFocus | Jul. 13, 2012 | 17:15PM EST
  45. UPDATE: Bank of America Raises PT on Orexigen Therapeutics from $7 to $9.

    Benzinga | Jul. 12, 2012 | 02:45AM EST
  46. Benzinga's Top Pre-Market Gainers

    Benzinga | Jul. 11, 2012 | 02:13AM EST
  47. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected

    Benzinga | Jul. 11, 2012 | 00:40AM EST
  48. Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples Inc, and Orexigen ...

    GuruFocus | Jul. 8, 2012 | 13:30PM EST
  49. These Are Four of the Hottest Biotechs in the Market Right Now

    Benzinga | Jul. 5, 2012 | 07:19AM EST
  50. Orexigen Therapeutics Falls 6% on Profit Taking

    Benzinga | Jun. 29, 2012 | 09:13AM EST
Trading Center